Oncological diseases can affect essentially any body system from the skin, bones, organs, to blood, necessitating a broad range of imaging approaches. At DICE, our scientific and radiologic experience helps ensures the appropriate imaging modalities are specifically selected to fit your unique trial's needs and design. From well-established morphological and functional imaging techniques, to novel fusion imaging modalities, our radiologists will deliver high quality, broad proficiency across disease type and imaging interpretation criteria.

Our expert team will seamlessly work across multiple interpretation criteria combining the well-established RECIST-based guidelines with the novel evaluation criteria.

We work in close collaboration with our skilled Statistics team should you request the development and validation of new or modified, trial-specific interpretation criteria or disease biomarkers.

Our areas of expertise include:

  • Solid malignancies, including:
    • Lung cancer
    • Breast cancer
    • Prostate cancer
    • Skin (melanoma, Merkel cell carcinoma...)
    • Head and neck tumors
    • Gastrointestinal tumors
    • Gynecologic cancers
    • Neuroendocrine tumors
    • Malignant bone tumors
    • Sarcomas
    • GIST tumors
  • Hematologic malignancies, including:
    • Hodgkin disease
    • Non-Hodgkin lymphomas
    • Multiple myeloma
    • Waldenstrom macroglobulinemia

Imaging modalities:

  • CT
  • MRI
  • PET/CT using 18F-FDG, 11C-choline, 11C-methionine or 68Ga-PSMA
  • PET/MRI using 18F-FDG
  • Ultrasound

Interpretation criteria:

  • Quantitative
    • RECIST
    • iRECIST
    • mRECIST
    • EORTC
    • Choi criteria
  • Qualitative
    • Deauville score
    • Lugano score


Join the DICE team!

Check out the current job openings.